Evidence map›Paper›PMID 36002176›Full record

ArticleBMJ open diabetes research & care2022

Sugar is not always sweet: exploring the relationship between hyperglycemia and COVID-19 in a predominantly African American population.

Samara Skwiersky, Sabrina Rosengarten, Talia Meisel, Francesca Macaluso, Megan Chang, Alastair Thomson, Brandon Da Silva, Alvin Oommen, Jerome Salvani, Mary Ann Banerji

Open access · goldAbstract read
In one paragraph

Article in BMJ open diabetes research & care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Samara SkwierskyInternal Medicine, SUNY Downstate Health Sciences University, Brooklyn, New York, USA.ORCID 0000-0002-0277-8575
Sabrina RosengartenCollege of Medicine, SUNY Downstate Health Sciences University, Brooklyn, New York, USA.
Talia MeiselCollege of Medicine, SUNY Downstate Health Sciences University, Brooklyn, New York, USA.
Francesca MacalusoCollege of Medicine, SUNY Downstate Health Sciences University, Brooklyn, New York, USA.
Megan ChangCollege of Medicine, SUNY Downstate Health Sciences University, Brooklyn, New York, USA.
Alastair ThomsonInternal Medicine, SUNY Downstate Health Sciences University, Brooklyn, New York, USA.
Brandon Da SilvaCollege of Medicine, SUNY Downstate Health Sciences University, Brooklyn, New York, USA.
Alvin OommenCollege of Medicine, SUNY Downstate Health Sciences University, Brooklyn, New York, USA.
Jerome SalvaniInternal Medicine, SUNY Downstate Health Sciences University, Brooklyn, New York, USA.
Mary Ann BanerjiEndocrinology, SUNY Downstate Health Sciences University, Brooklyn, New York, USA MaryAnn.Banerji@downstate.edu.
SUNY Downstate Health Sciences University · USMontefiore Medical Center · USRobert Wood Johnson University Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe purpose of this study is to examine the effect of admission glucose in patients hospitalized with COVID-19 with and without diabetes mellitus in a largely African American cohort. DESIGN AND

methodsThis study included 708 adults (89% non-Hispanic Black) admitted with COVID-19 to an urban hospital between 1 March and 15 May 2020. Patients with diabetes were compared with those without and were stratified based on admission glucose of 140 and 180 mg/dL. Adjusted ORs were calculated for outcomes of mortality, intubation, intensive care unit (ICU) admission, acute kidney injury (AKI), and length of stay based on admission glucose levels.

resultsPatients with diabetes with admission glucose >140 mg/dL (vs <140 g/dL) had 2.4-fold increased odds of intubation (95% CI 1.2 to 4.6) and 2.1-fold increased odds of ICU admission (95% CI 1.0 to 4.3). Patients with diabetes with admission glucose >180 mg/dL (vs <180 g/dL) had a 1.9-fold increased mortality (95% CI 1.2 to 3.1). Patients without diabetes with admission glucose >140 mg/dL had a 2.3-fold increased mortality (95% CI 1.3 to 4.3), 2.7-fold increased odds of ICU admission (95% CI 1.3 to 5.4), 1.9-fold increased odds of intubation (95% CI 1.0 to 3.7) and 2.2-fold odds of AKI (95% CI 1.1 to 3.8). Patients without diabetes with glucose >180 mg/dL had 4.4-fold increased odds of mortality (95% CI 1.9 to 10.4), 2.7-fold increased odds of intubation (95% CI 1.2 to 5.8) and 3-fold increased odds of ICU admission (95% CI 1.3 to 6.6).

conclusionOur results show hyperglycemia portends worse outcomes in patients with COVID-19 with and without diabetes. While our study was limited by its retrospective design, our findings suggest that patients presenting with hyperglycemia require closer observation and more aggressive therapies.

Indexed as

Acute Kidney InjuryCOVID-19Diabetes MellitusHyperglycemiaAdultBlack or African AmericanGlucoseHumansRetrospective StudiesSugarsGlucoseSugarsAfrican AmericansCOVID-19diabetes mellitus, type 2hyperglycemia

Identifiers

PMID36002176
PMCPMC9412045
OpenAlexW4292939251

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.